Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ONTY's Cash to Debt is ranked higher than
81% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ONTY: No Debt )
ONTY' s 10-Year Cash to Debt Range
Min: 5.92   Max: No Debt
Current: No Debt

Interest Coverage No Debt
ONTY's Interest Coverage is ranked higher than
58% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ONTY: No Debt )
ONTY' s 10-Year Interest Coverage Range
Min: 1060.29   Max: 9999.99
Current: No Debt

1060.29
9999.99
F-Score: 3
Z-Score: 3.00
M-Score: -1.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -37.59
ONTY's ROE (%) is ranked higher than
73% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ONTY: -37.59 )
ONTY' s 10-Year ROE (%) Range
Min: -163.15   Max: 45.34
Current: -37.59

-163.15
45.34
ROA (%) -34.13
ONTY's ROA (%) is ranked higher than
71% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. ONTY: -34.13 )
ONTY' s 10-Year ROA (%) Range
Min: -133.9   Max: 24.26
Current: -34.13

-133.9
24.26
ROC (Joel Greenblatt) (%) -1775.09
ONTY's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. ONTY: -1775.09 )
ONTY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8811.02   Max: 661.2
Current: -1775.09

-8811.02
661.2
EBITDA Growth (3Y)(%) 2.30
ONTY's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ONTY: 2.30 )
ONTY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -60   Max: 29.6
Current: 2.3

-60
29.6
EPS Growth (3Y)(%) 2.20
ONTY's EPS Growth (3Y)(%) is ranked higher than
81% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ONTY: 2.20 )
ONTY' s 10-Year EPS Growth (3Y)(%) Range
Min: -60.4   Max: 28.7
Current: 2.2

-60.4
28.7
» ONTY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ONTY Guru Trades in Q4 2013

Paul Tudor Jones 39,902 sh (New)
Jean-Marie Eveillard 2,624,987 sh (+15.37%)
Murray Stahl 32,333 sh (unchged)
Jim Simons 156,700 sh (-77.85%)
» More
Q1 2014

ONTY Guru Trades in Q1 2014

George Soros 89,600 sh (New)
Jean-Marie Eveillard 2,724,987 sh (+3.81%)
Murray Stahl 32,333 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 30,757 sh (-22.92%)
» More
Q2 2014

ONTY Guru Trades in Q2 2014

Paul Tudor Jones 31,457 sh (+2.28%)
Murray Stahl 32,333 sh (unchged)
George Soros Sold Out
Jean-Marie Eveillard 2,384,039 sh (-12.51%)
» More
Q3 2014

ONTY Guru Trades in Q3 2014

Steven Cohen 721,075 sh (New)
Murray Stahl 32,333 sh (unchged)
Jean-Marie Eveillard Sold Out
Paul Tudor Jones 22,957 sh (-27.02%)
» More
» Details

Insider Trades

Latest Guru Trades with ONTY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-09-30 Sold Out 0.02%$2 - $3.29 $ 1.8-29%0
George Soros 2014-06-30 Sold Out $2.35 - $3.5 $ 1.8-39%0
George Soros 2014-03-31 New Buy$1.71 - $3.89 $ 1.8-33%89600
Jean-Marie Eveillard 2013-09-30 Add 75.63%0.01%$1.59 - $2.18 $ 1.83%2275287
Andreas Halvorsen 2013-06-30 Sold Out 0.05%$1.57 - $2.63 $ 1.8-16%0
Jean-Marie Eveillard 2013-06-30 Add 547.75%0.01%$1.57 - $2.63 $ 1.8-16%1295499
Jean-Marie Eveillard 2013-03-31 New Buy$1.86 - $2.35 $ 1.8-14%200000
Jean-Marie Eveillard 2012-03-31 Sold Out 0.0033%$4.16 - $8.96 $ 1.8-72%0
Jean-Marie Eveillard 2011-12-31 Add 33.33%$5.84 - $8.25 $ 1.8-74%100000
Andreas Halvorsen 2011-09-30 New Buy0.22%$5.95 - $10.2 $ 1.8-76%3110650
Jean-Marie Eveillard 2011-09-30 Reduce -66.67%0.01%$5.95 - $10.2 $ 1.8-76%75000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.08
ONTY's P/B is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. ONTY: 1.08 )
ONTY' s 10-Year P/B Range
Min: 0.75   Max: 23.93
Current: 1.08

0.75
23.93
EV-to-EBIT -2.75
ONTY's EV-to-EBIT is ranked higher than
71% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ONTY: -2.75 )
ONTY' s 10-Year EV-to-EBIT Range
Min: -170.5   Max: 10.1
Current: -2.75

-170.5
10.1
Current Ratio 17.40
ONTY's Current Ratio is ranked higher than
93% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ONTY: 17.40 )
ONTY' s 10-Year Current Ratio Range
Min: 1.67   Max: 36.71
Current: 17.4

1.67
36.71
Quick Ratio 17.40
ONTY's Quick Ratio is ranked higher than
93% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ONTY: 17.40 )
ONTY' s 10-Year Quick Ratio Range
Min: 0.95   Max: 36.71
Current: 17.4

0.95
36.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.88
ONTY's Price/Net Cash is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. ONTY: 1.88 )
ONTY' s 10-Year Price/Net Cash Range
Min: 1.03   Max: 38.63
Current: 1.88

1.03
38.63
Price/Net Current Asset Value 1.85
ONTY's Price/Net Current Asset Value is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. ONTY: 1.85 )
ONTY' s 10-Year Price/Net Current Asset Value Range
Min: 0.95   Max: 22.98
Current: 1.85

0.95
22.98
Price/Tangible Book 1.56
ONTY's Price/Tangible Book is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. ONTY: 1.56 )
ONTY' s 10-Year Price/Tangible Book Range
Min: 0.84   Max: 81
Current: 1.56

0.84
81
Earnings Yield (Greenblatt) -36.40
ONTY's Earnings Yield (Greenblatt) is ranked higher than
53% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. ONTY: -36.40 )
ONTY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 9.9   Max: 487.4
Current: -36.4

9.9
487.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:3O6.Germany,
Oncothyreon Inc was incorporated on September 7, 2007. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's cancer vaccine product candidate, tecemotide, formerly known as L-BLP25 or Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of tecemotide. The Company is also conducting Phase 1 trial for ONT-10, a cancer vaccine. The Company's pipeline of products includes immunotherapies and small molecules. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. As of December 31, 2013 the Company owned approximately 25 U.S. patents and patent applications. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.
» More Articles for ONTY

Headlines

Articles On GuruFocus.com
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
pro-longs life Jul 30 2011 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
cooldecency99 note on ONTY May 01 2010 
creiter note on ONTY Jan 03 2010 


More From Other Websites
ONCOTHYREON INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Dec 12 2014
Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium Dec 12 2014
Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380 Dec 12 2014
Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium Dec 12 2014
Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380 Dec 12 2014
Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% Nov 28 2014
ONCOTHYREON INC. Financials Nov 14 2014
Oncothyreon to Present at Stifel 2014 Healthcare Conference Nov 12 2014
Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial... Nov 10 2014
Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial... Nov 10 2014
10-Q for Oncothyreon, Inc. Nov 08 2014
Oncothyreon posts 3Q loss Nov 06 2014
Oncothyreon posts 3Q loss Nov 06 2014
ONCOTHYREON INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014
Oncothyreon Reports Third Quarter 2014 Financial Results Nov 06 2014
Oncothyreon Announces Third Quarter 2014 Financial Results Conference Call Oct 30 2014
Oncothyreon Announces Third Quarter 2014 Financial Results Conference Call Oct 30 2014
ONCOTHYREON INC. Files SEC form 8-K/A, Financial Statements and Exhibits Oct 22 2014
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside Oct 21 2014
Coverage initiated on Oncothyreon by H.C. Wainwright Oct 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK